Categories
Diabetes Observational Study

The Absolute Risk of Incident Type 2 Diabetes Following Exposure to Systemic Corticosteroids in Selected Steroid-related and Phenotypic Groups

Ambery P, Adamsson Eryd S, Jenkins-Jones S, Heywood B, Berni E, Brown M N, Astbury C, Hunt P, Currie C J. 6 Jul 2022

Categories
Diabetes Retrospective Study

Glucose Control and Weight Change Associated with Treatment with Exenatide Compared with Basal Insulin: A Retrospective Study

Morgan C L, Qiao Q, Grandy S, Johnsson K, Jenkins-Jones S, Holden S E & Currie C J. 09 Jan 2018

Categories
Diabetes

Impact of differing glucose-lowering regimens on the pattern of association between glucose control and survival

Currie C J, Holden S E, Jenkins-Jones S, Morgan C L, Voss B, Rajpathak S N, Alemayehu B, Peters J R and Engel S S. 09 Nov 2017

Categories
Diabetes

Evaluation of the clinical effectiveness in routine practice of fluocinolone acetonide 190 µg intravitreal implant in people with diabetic macular edema

Holden S E, Currie C J, Owens D R. 07 Sep 2017

Categories
Diabetes

Direct medical costs of severe hypoglycaemic events in patients with type 2 diabetes in England: A retrospective database study

Holbrook T, Tang Y, Das R, Shankar R R, Tunceli K, Williams J, Radican L, Holden S E, Morgan C L, Piercy J, Currie C J. 23 May 2017

Categories
Comparitive Effectiveness Diabetes

Cardiovascular events and all-cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs: A Bayesian meta-analysis of survival data

Bain S, Druyts E, Balijepalli C, Baxter C A, Currie C J, Das R, Donnelly R, Khunti K, Langerman H, Leigh P, Siliman G, Thorlund K, Toor K, Vora H J, Mills E J. 14 Nov 2016

Categories
Diabetes

Diabetes and Cancer

Holden S E. 19 Jan 2016

Categories
Diabetes Diabetes Obesity & Metabolism

Glucose-lowering with exogenous insulin monotherapy in type 2 diabetes: dose association with all-cause mortality, cardiovascular events and cancer

Holden S E, Jenkins-Jones S, Morgan C L, Schernthaner G, Currie C J. 14 Nov 2014

We use cookies to give you the best online experience. By agreeing you accept the use of cookies in accordance with our cookie policy.

Privacy Settings saved!
Privacy Settings

When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.

These cookies are necessary for the website to function and cannot be switched off in our systems.

In order to use this website we use the following technically required cookies
  • wordpress_test_cookie
  • wordpress_logged_in_
  • wordpress_sec

Decline all Services
Accept all Services

MEET OUR BRANDS

About HDS

  • Our company
  • Boilerplate copy

HUMAN DATA SCIENCE

Logo
  • The HDS Logo
  • Logo mark
  • Clearspace
  • Backgrounds
Colours
  • Primary Palette
  • Secondary Palette

LIVINGSTONEIQ

Logo
  • The Livingstone Logo
  • Logo mark
  • Clearspace
  • Backgrounds
Colours
  • Primary Palette
  • Secondary Palette

PREVALENCEUK

Logo
  • The PrevalenceUK Logo
  • Logo mark
  • Clearspace
  • Backgrounds
Colours
  • Primary Palette
  • Secondary Palette

TYPOGRAPHY

  • Typestack

VOICE AND TONE

ICONS

  • Icon basics
  • Design considerations
  • Icon styles